Month: June 2026

Introduction and Objective: Chronic opioid use is associated with high risk of overdose and developing substance use disorder. GLP-1RAs may influence reward-related neurobehavioral pathways, however, their real-world effects on opioid-related outcomes are unclear. We evaluated the association between GLP-1RA use and risk of opioid overdose among individuals with chronic opioid use.Methods: Using US claims data, […]

Introduction and Objective: The C-reactive protein-triglyceride-glucose index (CTI) is a composite biomarker reflecting insulin resistance and systemic inflammation. Large-scale evidence linking CTI to multiple chronic diseases and cause-specific mortality remains limited.Methods: We conducted a multicenter cohort study of middle-aged and older adults using the China Health and Retirement Longitudinal Study (CHARLS, n=5366) and US National […]

Introduction and Objective: Brown adipose tissue (BAT) plays a key role in non-shivering thermogenesis and is strongly implicated in obesity and metabolic disease, and may offer an alternative therapeutic strategy for treating obesity and its related comorbidities.Methods: Starting from a BAT-ML (an in-house machine learning (ML)-derived BAT phenotype) GWAS, we investigated the relevance of these […]

Introduction and Objective: Electronic cigarettes (e-cigs) have become the main tobacco product used by youth. Although the effects of conventional cigarette use have been studied, the metabolic effects of e-cigs have yet to be explored. In mice on a high-fat diet (HFD), we have shown that e-cig treatment produces cardiac dysfunction in a lipolysis-dependent manner. […]

Introduction and Objective: Obesity and type 2 diabetes are strongly associated with accelerated cognitive decline. We tested whether chronic high-fat diet (HFD) feeding with sucrose intake impairs cognition in mice and whether TLC-1180, a novel mitochondrial protonophore, improves metabolic and neural deficits.Methods: Male C57BL/6J mice were fed regular chow (RC) or HFD with 1% sucrose […]

Introduction and Objective: Oral, small-molecule GLP-1RA receptor agonists hold significant promise to provide durable weight loss and improved long-term outcomes for those living with obesity, Type 2 diabetes or other chronic cardiometabolic disorders. The objective of this research was to demonstrate the differentiated profile of the oral GLP-1 receptor agonist and development candidate, AMB-702, with […]

Introduction and Objective: Amylin is an attractive target for obesity therapy. Eloralintide is a selective and potent once-weekly subcutaneously administered amylin analog peptide, which has demonstrated promising efficacy and safety profile in a 48-week clinical trial for obesity. ASC39 is a novel oral small molecule amylin receptor agonist development candidate. This study evaluates in vitro […]

Introduction and Objective: Uncoupling protein 1 (Ucp1) activation drives potent adipose thermogenesis, yet the target is widely considered undruggable by conventional therapeutic modalities. Targeting the Ucp1 promoter with small activating RNA (saRNA) offers a novel RNA activation (RNAa) approach to overcome this barrier. We evaluated the efficacy, body composition, and durability effects of LiCO-saUcp1—an adipose-biased, […]

Introduction and Objective: Lifestyle behaviors (LB) have gained widespread acceptance as a key component of diabetes management since first featured in the 2017 ADA Standard of Care, with emphasis on modifiable LB and practical screening tools to optimize diabetes prevention and management. However, clinical application of existing screening measures remains limited by their length and […]